Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9

por Saqub, Hera, Proetsch-Gugerbauer, Hannah, Bezrookove, Vladimir, Nosrati, Mehdi, Vaquero, Edith M., de Semir, David, Ice, Ryan J., McAllister, Sean, Soroceanu, Liliana, Kashani-Sabet, Mohammed, Osorio, Robert, Dar, Altaf A.
Publicado 2020